Drug Trial Radar · NCT06574009
Better Options for Chronic Cancer Pain
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
294
Planned (sponsor's estimate)
Start
Oct 7, 2025
Primary completion
Apr 1, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Aug 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This proposal is relevant to the 240,000 cancer survivors who continue to use opioids long after they have successfully completed treatment for cancer at the VHA, placing them at risk of opioid addiction and overdose, and other opioid-related problems. Yet, there are no programs at the VHA to help them find alternatives to opioids, nor evidence to inform the choice of interventions. This study will meet these needs by examining four interventions that are effective at reducing opioid use in patients with chronic musculoskeletal pain but have yet to be tested in cancer survivors on long term opioid therapy. The proposed work is relevant to the VHA Pain Office's mission to provide Veterans better pain management while limiting the risks of long-term opioid therapy and it aligns with VHA Research and Development's priority to examine clinical interventions for tapering opioids. Successful completion this project will keep VHA at the forefront of the battle against the opioid epidemic with a strategy that may be adapted to address the same needs in non-Veterans.
Conditions
- Chronic Pain
- Cancer Survivor
- Opioid Dependence
Interventions
Multimodal pain careBehavioral
Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage
Medication optimizationDrug
Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.
Buprenorphine rotationDevice
Subjects randomized to this arm at 6 months will be offered the chance to rotate from their full mu agonist opioid to buprenorphine using a standardized protocol
Opioid taperingOther
Subjects randomized to tapering will receive recommendations based upon the VA PBM's opioid tapering reference guide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Opioid dose reduction + Pain response (binary: yes/no)Time frame: 9 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Richard L. Roudebush VA Medical Center, Indianapolis, IN
Indianapolis, Indiana · Not yet recruiting
VA Ann Arbor Healthcare System, Ann Arbor, MI
Ann Arbor, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.